- Limb-Girdle Muscular Dystrophy (LGMD), a group of genetically inherited neuromuscular disorders primarily affecting the shoulder and pelvic girdles, is increasingly drawing attention in the medical field due to advances in genetic testing, gene therapy, and rare disease research. The market is witnessing rapid growth as early diagnosis and targeted treatment options become more accessible through emerging biotechnological innovations and molecular diagnostics
- The escalating demand for effective LGMD therapies is primarily fueled by rising awareness among patients and caregivers, supportive regulatory incentives for orphan drugs, and an expanding pipeline of novel treatments including gene therapies, exon-skipping therapies, and enzyme replacement therapies. Increased advocacy and patient registries are also helping streamline clinical research and data collection for rare subtypes
- North America dominated the limb-girdle muscular dystrophy market with the largest revenue share of 41.3% in 2024, attributed to advanced healthcare infrastructure, strong presence of leading pharmaceutical and biotechnology companies, and early adoption of gene therapies. The U.S. continues to lead in clinical trials and FDA designations for LGMD-related therapies, with substantial funding support from public and private sectors
- Asia-Pacific is projected to be the fastest-growing region in the limb-girdle muscular dystrophy market, registering a CAGR of 19.6% from 2025 to 2032, driven by improving healthcare access, growing genetic testing capabilities, and increasing investments in rare disease diagnostics and treatments across countries such as China, Japan, and India
- The weakness of the proximal muscles of the hip and shoulder segment dominated the market with the largest revenue share of 46.5% in 2024, primarily due to its prevalence across various subtypes of LGMD. This symptom is often the earliest clinical manifestation, leading to diagnostic evaluation and therapeutic intervention
